Clinical TrialJun 3, 2026, 08:01 AM
Lexicon to Present Clinical Data at ADA 2026; Sotagliflozin NDA on Track
AI Summary
Lexicon Pharmaceuticals announced it will present clinical data for sotagliflozin in Type 1 diabetes (T1D) and pilavapadin in diabetic peripheral neuropathic pain (DPNP) at the American Diabetes Association (ADA) 2026 Scientific Sessions. The company highlighted continued evidence of sotagliflozin's mechanistic benefits, reinforcing its potential ahead of a planned New Drug Application (NDA) resubmission for T1D, which remains on track for mid-year 2026. Presentations will include pooled analysis from inTandem trials for sotagliflozin and Phase 1 study results for pilavapadin.
Key Highlights
- Lexicon Pharmaceuticals to present clinical data for sotagliflozin and pilavapadin at ADA 2026 Scientific Sessions.
- Data from clinical studies of sotagliflozin in Type 1 diabetes (T1D) will be presented.
- Data from clinical studies of pilavapadin in diabetic peripheral neuropathic pain (DPNP) will be presented.
- New Drug Application (NDA) resubmission for sotagliflozin in T1D is on track for mid-year 2026.
- Sotagliflozin is an oral inhibitor of SGLT2 and SGLT1 proteins.
- Pilavapadin is a potent, once-daily, orally administered, selective AAK1 inhibitor.
Price Impact
More from LXRX